FDA’s Social Media Guidance: As Industry Waits, How Watchful Should It Be?

FDA’s Office of Prescription Drug Promotion will soon release four draft guidance documents on various aspects of drug companies’ use of social media to convey product information, Director Thomas Abrams said.

While it is impossible to say exactly when or in what order the agency will release the documents due to the need for legal review and other internal processes, the intent is to address the use of links, when and how drug firms should correct misinformation posted on a third-party website, fulfillment of post-marketing reporting requirements, and fulfillment of regulatory requirements for tools associated with space limitations,